Zydus Lifesciences rose 3% to an intra-day high of Rs 930 after the company received approval from the US FDA to manufacture ...
The rise in the Zydus Lifesciences shares came after the company received final approval from the United States Food and Drug ...
Zydus Lifesciences received final USFDA approval to manufacture Apalutamide tablets for prostate cancer, following last ...
The company got the nod to manufacture and market apalutamide tablets, 60 mg, the generic equivalent of Erleada tablets, 60 ...
Zydus Lifesciences shares rose 8.34 per cent on March 19, touching an intraday high of Rs 910.30 at 1:00 PM when the company ...
Apalutamide is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive ...
Investors in pharma and auto stocks are anxious ahead of the April 2 deadline for US tariffs. Despite a 6% fall over three ...
India's Zydus Lifesciences said on Tuesday it will acquire an 85.6% stake in France's Amplitude Surgical for 256.8 million euros (nearly $280 million) as part of its plans to expand further in the ...
9don MSN
On March 18, post-market hours, Zydus Lifesciences announced that it has received approval from the United States Food & Drug ...
As per the IQVIA MAT January 2025 data, apalutamide tablets registered annual sales of $1099.80 million in the United States markets.
Inspection occurred from March 10, 2025 to March 14, 2025 and ended with no observations with full compliance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results